China Solicits Comments on Drug GCP

Published date21 December 2016
Law FirmRopes & Gray LLP
AuthorKatherine Wang
Subject MatterChina,International Harmonization,Comment Period,Best Practices,China FDA,Pharmaceutical Industry

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT